Fluorocholine PET/CT in patients with prostate cancer: initial experience. - Wikidata - wikimedia - TriplyDB

Fluorocholine PET/CT in patients with prostate cancer: initial experience.

Fluorocholine PET/CT in patients with prostate cancer: initial experience.

http://www.wikidata.org/entity/Q36109495

about

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report Imaging of prostate carcinoma Update on positron emission tomography for imaging of prostate cancer Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey.Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.The next generation of positron emission tomography radiopharmaceuticals in oncology.PET/CT Imaging and Radioimmunotherapy of Prostate Cancer Functional imaging for prostate cancer: therapeutic implications.Emission guided radiation therapy for lung and prostate cancers: a feasibility study on a digital patient.Imaging localized prostate cancer: current approaches and new developments.Imaging in genitourinary cancer from the urologists' perspective.Feasibility of 18F-fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans--first results.Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm.Novel tracers and their development for the imaging of metastatic prostate cancer.Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.Pre-clinical and clinical evaluation of nuclear tracers for the molecular imaging of vulnerable atherosclerosis: an overview Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer.68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.Modalities for imaging of prostate cancer.State-of-the-art uroradiologic imaging in the diagnosis of prostate cancer.18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer.Choline PET/CT for imaging prostate cancer: an update.A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer.Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine.Biodisposition and metabolism of [(18)F]fluorocholine in 9L glioma cells and 9L glioma-bearing fisher rats.PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer.Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.Comparison of PET/CT and whole-mount histopathology sections of the human prostate: a new strategy for voxel-wise evaluation.Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate canc AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer.[Potential of PET/MRI for diagnosis of prostate cancer].Potential of hybrid ¹⁸F-fluorocholine PET/MRI for prostate cancer imaging.The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer.Comparative effectiveness of [(18) F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer.Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer.Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens.

P2860

Q26747480-8F58748D-8EAD-462B-A3BA-FA231A296585 Q26865815-74E9282C-4ECE-4D95-A918-3BF7CECE21E7 Q27026828-9ABC4295-D061-4833-936A-40A03455163F Q34040036-950A6880-CBFC-4821-B7B0-483C86BE3C6D Q34681143-C46B5254-0D97-4D2E-9333-73459D73028F Q35043569-16A4DBA7-E0FF-4EA7-B806-2CB63697260E Q35515150-3F76C5FE-BAA6-4248-8F75-CC4CDFAFDA78 Q35525690-00FF1834-9C42-43F2-9280-A279FB4A4B05 Q36085426-541B0AF0-3F00-4B94-847D-22E97C9D3AA8 Q36128629-D449FA48-E934-434A-988E-7A6F71EE8A79 Q36419938-FB02CC6A-A764-4D6E-AD92-7A4FA2B1B3AC Q36469177-87B89D38-ACB4-4524-9442-56BEB8913A1C Q36834536-D00D0422-3AFA-4479-B736-4F697C429E87 Q37053606-3C84A9B6-9C8B-4CED-89B8-FBE4131F63D2 Q37086178-E099FA71-3032-4B74-B623-DF96A426A89A Q37321810-C6B58CFC-F81D-485A-ADCF-D70A1A51F189 Q37350456-1624EDC1-D382-443A-8F32-8E1087129918 Q37438144-3C01F1C0-430A-4115-AD03-0BA7A5FC7B68 Q37457888-94A98C6D-F707-4ED9-B4AA-AE6F0FBC6199 Q37707083-6E585FA0-9B2D-4BDD-A216-E52E1E07E1EE Q37719273-5041E642-9782-42FF-9A17-460E5CFD6DE2 Q37878465-2336649F-39D4-49D8-8082-F9640070D6B2 Q37918311-05A3CB67-D2E9-452E-AB9B-FF4038780551 Q38098124-B0F92C44-9273-4AB8-9F70-3CDB4C8B755B Q38103180-7BC53871-2FC0-4C62-AD98-551E09EEC636 Q38190115-8BE90C1F-6BA1-4791-A343-5E53423EC867 Q38479113-0DD7440D-2C85-4D1A-9267-E76E8C0A782C Q38532173-B3C0F3CB-BF64-495F-B9B5-BAF1BFD7C894 Q39242140-80942B52-82C8-4117-9599-F7A7F05A28CE Q39636721-F716F358-C2AE-4D4D-9295-C2A2EBC447EA Q39710843-9468BBB4-EAD4-456E-BE1D-9DD81811097C Q41436127-F2B11492-7B08-4F6F-9B16-E41DE0055198 Q41482900-8D5FBD34-0818-4ECB-AF05-72EE8AF60F03 Q42551982-5D0FC891-1686-470E-8B92-DE9A491C4431 Q43636204-75C5705E-7DF9-4970-8108-84CAF63B546D Q45012077-EACE61D3-EAF4-499B-8A91-A4046F938316 Q46813213-148E8EEF-6EB5-4B41-98E2-66FA92F3A31F Q50613922-1B001DFB-FCB4-4C14-B658-CEC6FB8FF52E Q50953102-CE32AAA5-AE05-41C3-BD0C-CADF1D951682 Q51262657-B3F34BB6-F0F5-44A7-93FF-9A343ED4FDC5

P2860

Fluorocholine PET/CT in patients with prostate cancer: initial experience.

http://www.wikidata.org/entity/Q36109495

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Fluorocholine PET/CT in patients with prostate cancer: initial experience.

@ast

Fluorocholine PET/CT in patients with prostate cancer: initial experience.

@en

type

label

Fluorocholine PET/CT in patients with prostate cancer: initial experience.

@ast

Fluorocholine PET/CT in patients with prostate cancer: initial experience.

@en

prefLabel

Fluorocholine PET/CT in patients with prostate cancer: initial experience.

@ast

Fluorocholine PET/CT in patients with prostate cancer: initial experience.

@en

P1433

Q36109495-C4DF6B5D-4FC3-47CB-825B-5EDCE0A04839

P1476

Q36109495-85E484BE-5B16-4579-B09A-65CB2E708954

P2093

Q36109495-14BE7488-5ED8-4CDB-80A4-B75E21994842

Q36109495-606B910A-32D5-48E3-85C2-B57857854301

Q36109495-7B7184D1-EC41-47CE-898E-C3DB48F5D043

Q36109495-9DCB2A3A-BBBE-497A-A2B0-32E196E3C7C6

Q36109495-B76CEFD5-63C0-443A-9D59-0CF565353CA5

Q36109495-C03EFD49-5074-4C1A-8A52-62CC6E0F43FB

Q36109495-CFDB4736-1B38-4787-976A-CDFD0A3CC257

Q36109495-FF9C6C5B-C271-4C78-9865-DA25A5301997

P304

Q36109495-FF982763-C286-4B63-B653-1014A37D8A12

P31

Q36109495-6A09FA38-1FB9-4220-902C-915ECAF19AB2

P356

Q36109495-78338F14-BB41-458E-A2FD-3CB330AACF94

P407

Q36109495-85ECC517-611B-4412-8F4C-8DF9ADBCBFA6

P433

Q36109495-93953EE9-DA3A-4FCC-BA06-E7039745CDB0

P478

Q36109495-B6769430-7CA6-42B2-A329-92354943B22A

P577

Q36109495-1D768984-AB53-4DB2-A41B-96770F41E14F

P5875

Q36109495-95B377B3-69D6-41AA-951A-43A41A897A42

P698

Q36109495-F12CF106-1569-415F-A288-DDA6235923C2

P356

RADIOL.2352040494

P1433

P1476

Fluorocholine PET/CT in patients with prostate cancer: initial experience.

@en

P2093

Daniel T Schmid

http://www.w3.org/2001/XMLSchema#string

Gerhard W Goerres

http://www.w3.org/2001/XMLSchema#string

Gerrit Westera

http://www.w3.org/2001/XMLSchema#string

Gustav K von Schulthess

http://www.w3.org/2001/XMLSchema#string

Hubert John

http://www.w3.org/2001/XMLSchema#string

Roland Zweifel

http://www.w3.org/2001/XMLSchema#string

Thomas F Hany

http://www.w3.org/2001/XMLSchema#string

Tibor Cservenyak

http://www.w3.org/2001/XMLSchema#string

P304

623-628

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1148/RADIOL.2352040494

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

235

http://www.w3.org/2001/XMLSchema#string

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7880194

http://www.w3.org/2001/XMLSchema#string

P698

15858102

http://www.w3.org/2001/XMLSchema#string